Canntab Therapeutics Limited

OTCPK:CTAB.F Stock Report

Market Cap: US$38.0

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Canntab Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Richard Goldstein

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure6.8yrs
CEO ownershipn/a
Management average tenure6.5yrs
Board average tenure6.8yrs

Recent management updates

No updates

Recent updates

No updates

CEO Compensation Analysis

How has Richard Goldstein's remuneration changed compared to Canntab Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Feb 28 2023n/an/a

-CA$3m

Nov 30 2022n/an/a

-CA$3m

Aug 31 2022n/an/a

-CA$4m

May 31 2022n/an/a

-CA$4m

Feb 28 2022n/an/a

-CA$5m

Nov 30 2021n/an/a

-CA$5m

Aug 31 2021n/an/a

-CA$4m

May 31 2021n/an/a

-CA$4m

Feb 28 2021n/an/a

-CA$3m

Nov 30 2020n/an/a

-CA$3m

Aug 31 2020n/an/a

-CA$3m

May 31 2020CA$130kCA$120k

-CA$3m

Feb 29 2020n/an/a

-CA$2m

Nov 30 2019n/an/a

-CA$2m

Aug 31 2019n/an/a

-CA$2m

May 31 2019CA$138kCA$120k

-CA$2m

Compensation vs Market: Insufficient data to establish whether Richard's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Richard's compensation with company performance.

CEO

Richard Goldstein (63 yo)

6.8yrs
Tenure
CA$129,600
Compensation

Mr. Richard C. Goldstein is the Co-founder of Canntab Therapeutics Limited and serves as Interim Chief Executive Office from July 31, 2022. He serves as Chief Financial Officer of Canntab Therapeutics Limi...

Leadership Team

NamePositionTenureCompensationOwnership
Richard Goldstein
Interim CEO6.8yrsCA$129.60kno data
Barry Polisuk
Secretary & Independent Director6.8yrsCA$62.28kno data
Joshi Laxminarayan
Chief Scientific Officer4.8yrsno datano data
Eric Malinski
Director of Marketing6.1yrsno datano data
6.5yrs
Average Tenure

Experienced Management: CTAB.F's management team is seasoned and experienced (6.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Richard Goldstein
Interim CEO6.8yrsCA$129.60kno data
Barry Polisuk
Secretary & Independent Director6.8yrsCA$62.28kno data
Lorne Gertner
Member of Advisory Boardno datano datano data
Vitor Fonseca
Independent Director6.8yrsno datano data
Hugh Sutherland
Member of Advisory Boardno datano datano data
Bob Woloschuk
Member of Advisory Board6.8yrsno datano data
Sabrina Ramkellawan
Member of Advisory Boardno datano datano data
Eric Hatashita
Member of Advisory Boardno datano datano data
6.8yrs
Average Tenure
66yo
Average Age

Experienced Board: CTAB.F's board of directors are considered experienced (6.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/16 18:51
End of Day Share Price 2024/11/19 00:00
Earnings2023/02/28
Annual Earnings2022/05/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Canntab Therapeutics Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.